ReviewFrontiers in immunology2026
Mechanistic insights into gut microbiota dysbiosis in osteoarthritis based on the gut-joint axis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a highly prevalent degenerative joint disease characterized by articular cartilage degradation, extracellular matrix disruption, subchondral bone sclerosis, and osteophyte formation, pathological features that collectively impair joint function and significantly reduce patients' quality of life. Therefore, elucidating the systemic pathogenic mechanisms of OA is essential for enabling early diagnosis and implementing disease modifying interventions. Recent studies demonstrate that the gut microbiota, as a key regulatory factor, actively participates in OA pathogenesis via the bidirectional "gut-joint axis." Gut microbiota dysbiosis, including depletion of beneficial commensal bacteria, Th17/Treg imbalance, aberrant macrophage polarization, and impaired intestinal barrier integrity, disrupts host microbiota symbiosis and promotes low-grade systemic inflammation, thereby amplifying synovial inflammation, cartilage catabolism, and subchondral bone remodeling. Although accumulating evidence robustly links gut dysbiosis to OA progression, the precise molecular and cellular mechanisms, particularly how specific alterations in gut microbiota composition and metabolites contribute to OA onset and development, remain incompletely defined. This article summarizes current insights into the gut-joint axis in OA and OA-related risk factors, focusing on structural alterations in the gut microbiota and shifts in key metabolites driven by intestinal dysbiosis in OA. Based on this, targeting the gut microbiota is proposed as a promising therapeutic strategy for OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.